POZEN and AstraZeneca Amend Terms of Collaboration for Pain/Inflammation Combination Product

By Business Review Editor

Pharma Deals Review: Vol 2007 Issue 88 (Table of Contents)

Published: 1 Oct-2007

DOI: 10.3833/pdr.v2007.i88.274     ISSN: 1756-7874

Section: Features



Just over 13 months after the original deal was made, in August 2006, POZEN and AstraZeneca have mutually agreed to amend certain terms of their collaboration and licence agreement for the development and commercialisation of PN 400, a fixed dose combination of the proton pump inhibitor esomeprazole magnesium with the NSAID, naproxen, in a single tablet...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details